Yedida Y Bogachkov PhD,  —

IRLAB has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational medication, pirepemat (previously known as IRL752), which is intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. “Pirepemat has potential to be the first…

Parkinson’s UK is investing up to £3 million (about $3.96 million) over the next two-and-a-half years to support research into inflammation that could help in developing therapies to slow the progression of Parkinson’s disease. The funding will come through the organization’s Virtual Biotech program — the therapy development…

Supernus Pharmaceuticals has again applied to the U.S. Food and Drug Administration (FDA) requesting that its apomorphine infusion device (SPN-830), allowing continuous treatment of Parkinson’s disease motor symptoms, be approved. “SPN-830 is an important product candidate which, if approved by the FDA, represents a novel approach for PD…

People with Parkinson’s disease verbally communicate less than those without the neurodegenerative disorder, according to a recent study that discovered that patients speak about 60% less than their healthy peers. Apart from the tremors and movement issues associated with Parkinson’s, the disease also can disrupt aspects of a…

UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein —…

A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at Lund Universit’s strategic research area Multipark and senior attending physician at Skåne University Hospital,…

An interdisciplinary research team from William and Mary University and Virginia Commonwealth University (VCU) are working on artificial intelligence programming to help develop a wearable device to treat freezing of gait (FoG), the temporary inability to move while walking, which is a motor symptom of Parkinson’s disease. “Freezing of…

Applications are open for the Parkinson’s Foundation 2022 community grant cycle, with $1 million to be awarded to help fund community-based health, wellness, and education programs supporting those affected by Parkinson’s disease. Since 1957, the Foundation has invested more than $400 million toward  Parkinson’s research and clinical care.

Researchers at the biotech company Second Genome have identified specific intestinal bacterial strains that are either enriched or depleted in patients with Parkinson’s disease, according to a press release. The data were presented in a poster, titled “Strain-Level Meta-Analysis of Parkinson’s Disease-Associated Gut Microbiome,” at…

Yumanity Therapeutics announced that its investigational therapy, YTX-7739, worked to safely inhibit stearoyl-CoA desaturase — an enzyme thought to play a role in the alpha-synuclein-derived toxicity seen in Parkinson’s — in a Phase 1b clinical trial in people with mild-to-moderate disease. Data from this trial, conduced in the Netherlands, is…